Flagship Pioneering related stories
All articles and analysis
Nestlé Health Science invests $42.5 mln in VC-backed Pronutria BiosciencesNestlé Health Science invested $42.5 million in Pronutria Biosciences Inc, a biotechnology company based in Cambridge, Massachusetts. Pronutria was founded within VentureLabs, the startup incubator within Flagship Ventures. The company has also received funding from Fidelity Research & Management Group and Gurnet Point Capital.
- Indigo scores $56 mln in funding round led by Flagship
Indigo raised $56 million in a funding round led by Flagship Ventures, the company announced in a blogpost http://www.indigoag.com/point-of-view/introducing-indigo-harnessing-the-power-of-nature-to-help-farmers-feed-the-planet Cambridge, Massachusetts-based Indigo is harnessing bacteria to create resilient super-crops. Indigo, formerly called Symbiota, was formed within VentureLabs, Flagship’s in-house startup incubator.
- Tarveda Therapeutics scores $38 mln Series C
Tarveda Therapeutics (formerly known as Blend Therapeutics) has raised $38 million in Series C funding. Novo A/S and return backer New Enterprise Associates led the round. The other investors included Flagship Ventures, NanoDimension and Eminent Venture Capital. In conjunction with the financing, Nilesh Kumar of Novo Ventures (US) Inc. and Dr. Frank Torti of NEA have been added to Tarveda’s board of directors while Drew Fromkin has been appointed interim board chairman.Watertown, Massachusetts-based Tarveda is a biopharmaceutical company focused on treating patients with solid tumor cancers.
- Syros Pharma raises $40 mln
Syros Pharmaceuticals said Tuesday it closed a $40 million financing led by new investor Deerfield Management Company. Also participating were new investor Casdin Capital, as well as existing investors Fidelity Management and Research Company, WuXi Healthcare Ventures, Polaris Partners, Redmile Group, Aisling Capital and Alexandria Venture Investments. Cambridge, Massachusetts-based Syros is a biopharmaceutical company.
- Flagship Ventures provides $25 mln to Rubius Therapeutics
Cambridge, Massachusetts-based Rubius Therapeutics, a functionalized red blood cells developer focused on treating autoimmune conditions, metabolic diseases, cancer and other serious diseases, has launched with $25 million in funding. Flagship Ventures was the investor.
- Codiak racks up over $80 mln, appoints Williams as CEO and president
Codiak BioSciences Inc, which is focused on using exosomes to treat and diagnose cancer and other diseases, has secured over $80 million in committed funding. Codiak's investors include Fidelity Management and Research Company, the Alaska Permanent Fund and Alexandria Venture Investments. In addition to the funding, Codiak has appointed Dr. Douglas E. Williams as its founding president and chief executive officer. Previously, Williams worked at Biogen where he served as executive vice president of research and development.
- Flagship Ventures-backed Joule and Red Rock Biofuels to merge
Joule and Red Rock Biofuels, both of which are backed by Flagship Ventures, have agreed to merge. No financial terms were disclosed. Also, Dr. Brian Baynes, a partner at Flagship Ventures who is currently on the board of both Joule and Red Rock, will become president and CEO of the combined companies. Bedford, Massachusetts-based Joule is an alternative fuel developer while Red Rock Biofuels, which is located in Fort Collins, Colorado, is a provider of renewable biofuels.
- TARIS Biomedical scores $32 mln
TARIS Biomedical, which focuses on developing new treatments for urologic diseases, has secured $32 million in funding. Flagship Ventures led the round with participation from Polaris Venture Partners and RA Capital Management. Also, TARIS has appointed Dr. Christopher Cutie as vice president of clinical development. And, the company has named Kevin Finney, most recently Allergan's vice president and corporate development head, and Mark Iwicki, most recently president and CEO of Civitas Therapeutics, to its board of directors.